Over the last half-century, new medicines, technologies and biopharmaceutical research have revolutionized health care and helped millions of patients live longer, healthier lives. Building on this progress, America now is on the cusp of a golden era of biopharmaceutical discovery and personalized medicine. But certain actions must be taken at the policy level to ensure that the marketplace evolves at the pace of scientific advances and that patient needs and preferences are kept central. These policy solutions represent a commitment to a stronger U.S. health care market and to our future health system as a whole.
We need to modernize the FDA to keep pace with scientific discovery and to enable a more competitive, innovative and sustainable ecosystem.
We need to encourage value-driven payment models, and to remove the hurdles making it difficult for innovative, sensible payer/manufacturer arrangements to emerge.
We need to make more information on health care out-of-pocket costs and quality available to patients.
We need to address market distortions like the rapidly growing 340B
program or the risk adjuster for commercial insurance that does not
account for prescription drug costs.